CN1823061A - 用作肝脏x受体调节剂的吡咯－2,5－二酮衍生物 - Google Patents

用作肝脏x受体调节剂的吡咯－2,5－二酮衍生物 Download PDF

Info

Publication number
CN1823061A
CN1823061A CNA2004800198411A CN200480019841A CN1823061A CN 1823061 A CN1823061 A CN 1823061A CN A2004800198411 A CNA2004800198411 A CN A2004800198411A CN 200480019841 A CN200480019841 A CN 200480019841A CN 1823061 A CN1823061 A CN 1823061A
Authority
CN
China
Prior art keywords
phenyl
compound
amino
treatment
pyrrole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2004800198411A
Other languages
English (en)
Chinese (zh)
Inventor
J·博斯特伦
K·布里克曼
P·霍尔姆
P·桑德贝里
M·斯万松
C·维斯特隆德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of CN1823061A publication Critical patent/CN1823061A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
    • C07D207/444—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5
    • C07D207/456—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
CNA2004800198411A 2003-07-11 2004-07-08 用作肝脏x受体调节剂的吡咯－2,5－二酮衍生物 Pending CN1823061A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0316232.8A GB0316232D0 (en) 2003-07-11 2003-07-11 Therapeutic agents
GB0316232.8 2003-07-11

Publications (1)

Publication Number Publication Date
CN1823061A true CN1823061A (zh) 2006-08-23

Family

ID=27741983

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2004800198411A Pending CN1823061A (zh) 2003-07-11 2004-07-08 用作肝脏x受体调节剂的吡咯－2,5－二酮衍生物

Country Status (25)

Country Link
US (1) US7432288B2 (https=)
EP (1) EP1646626B1 (https=)
JP (1) JP2007521312A (https=)
KR (1) KR20060035748A (https=)
CN (1) CN1823061A (https=)
AR (1) AR045721A1 (https=)
AT (1) ATE399777T1 (https=)
AU (1) AU2004255999B2 (https=)
BR (1) BRPI0412472A (https=)
CA (1) CA2532056A1 (https=)
DE (1) DE602004014773D1 (https=)
ES (1) ES2308204T3 (https=)
GB (1) GB0316232D0 (https=)
IL (1) IL172760A0 (https=)
IS (1) IS8293A (https=)
MX (1) MXPA06000414A (https=)
MY (1) MY135821A (https=)
NO (1) NO20060081L (https=)
RU (1) RU2006102130A (https=)
SA (1) SA04250204B1 (https=)
TW (1) TW200503691A (https=)
UA (1) UA82109C2 (https=)
UY (1) UY28408A1 (https=)
WO (1) WO2005005417A1 (https=)
ZA (1) ZA200600222B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101456863B (zh) * 2007-12-14 2012-04-25 华北制药集团新药研究开发有限责任公司 Lxr激动剂及其制备方法和用途

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1634877B1 (en) * 2004-08-17 2011-06-22 Simpson Biotech Co., Ltd. Mixture and compounds from mycelia of antrodia camphorata and use thereof
US7505238B2 (en) * 2005-01-07 2009-03-17 Agnes Neves Woo ESD configuration for low parasitic capacitance I/O
SE0500055D0 (sv) 2005-01-10 2005-01-10 Astrazeneca Ab Therapeutic agents 3
CA2592771A1 (en) 2005-01-10 2006-07-13 Astrazeneca Ab Derivatives of isothiazol-3(2h)-one 1,1-dioxides as liver x receptor modulators
WO2007128458A1 (en) * 2006-04-28 2007-11-15 Laboratorios Del Dr. Esteve, S.A. Bicyclic tetrahydropyrrole compounds
ES2528797T3 (es) 2006-08-21 2015-02-12 Genentech, Inc. Compuestos de aza-benzotiofenilo y métodos de uso
MX2010014565A (es) 2008-07-01 2011-03-04 Genentech Inc Isoindolona y metodos de uso.
RU2509078C2 (ru) 2008-07-01 2014-03-10 Дженентек, Инк. Бициклические гетероциклы в качестве ингибиторов киназы мек
US20130274212A1 (en) 2010-09-07 2013-10-17 Snu R&Db Foundation Sesterterpene Compounds and Use Thereof
JP2013544837A (ja) 2010-12-03 2013-12-19 アラーガン インコーポレイテッド スフィンゴシン−１−リン酸（ｓ１ｐ）受容体モジュレーターとしての新規オキシムアゼチジン誘導体
AU2011336970A1 (en) 2010-12-03 2013-07-11 Allergan, Inc. Novel oxime derivatives as sphingosine 1-phosphate (S1P) receptor modulators
US10669296B2 (en) 2014-01-10 2020-06-02 Rgenix, Inc. LXR agonists and uses thereof
CA3010883A1 (en) 2016-01-11 2017-07-20 The Rockefeller University Methods for the treatment of myeloid derived suppressor cells related disorders
EP3713575A4 (en) 2017-11-21 2021-08-25 Rgenix, Inc. POLYMORPHS AND THEIR USES
HUE067466T2 (hu) 2019-12-13 2024-10-28 Inspirna Inc Fémsók és alkalmazásuk
US11753374B2 (en) * 2020-11-18 2023-09-12 Southern Reserach Institute Compounds for the treatment of acute and chronic kidney disease

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2338866A1 (en) 1998-07-30 2000-02-10 Japan Tobacco Inc. Disubstituted maleimide compound and pharmaceutical use thereof
ATE284387T1 (de) * 1998-10-08 2004-12-15 Smithkline Beecham Plc 3-(3-chloro-4-hydroxyphenylamino)-4-(2- nitrophenyl)-1h-pyrrol-2,5-dion als glykogen synthase kinase-3 inhibitor (gsk-3)
JP2004500332A (ja) * 1999-07-08 2004-01-08 テュラリク　インコーポレイテッド Ｈｄｌコレステロール値を上昇させる組成物および方法
AU6593600A (en) 1999-08-20 2001-03-19 Rei Asakai Drugs inhibiting cell death
GB0008264D0 (en) 2000-04-04 2000-05-24 Smithkline Beecham Plc Novel method and compounds

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101456863B (zh) * 2007-12-14 2012-04-25 华北制药集团新药研究开发有限责任公司 Lxr激动剂及其制备方法和用途

Also Published As

Publication number Publication date
CA2532056A1 (en) 2005-01-20
NO20060081L (no) 2006-02-08
IS8293A (is) 2006-02-09
BRPI0412472A (pt) 2006-09-19
US20060235015A1 (en) 2006-10-19
TW200503691A (en) 2005-02-01
AU2004255999A1 (en) 2005-01-20
AU2004255999B2 (en) 2007-08-02
JP2007521312A (ja) 2007-08-02
ATE399777T1 (de) 2008-07-15
KR20060035748A (ko) 2006-04-26
US7432288B2 (en) 2008-10-07
MY135821A (en) 2008-07-31
UA82109C2 (uk) 2008-03-11
WO2005005417A1 (en) 2005-01-20
IL172760A0 (en) 2006-04-10
AR045721A1 (es) 2005-11-09
GB0316232D0 (en) 2003-08-13
ES2308204T3 (es) 2008-12-01
SA04250204B1 (ar) 2008-03-23
ZA200600222B (en) 2007-04-25
HK1088320A1 (en) 2006-11-03
EP1646626B1 (en) 2008-07-02
RU2006102130A (ru) 2007-08-20
UY28408A1 (es) 2005-02-28
EP1646626A1 (en) 2006-04-19
DE602004014773D1 (de) 2008-08-14
MXPA06000414A (es) 2006-03-17

Similar Documents

Publication Publication Date Title
CN1114596C (zh) 联苯基衍生物
CN1823061A (zh) 用作肝脏x受体调节剂的吡咯－2,5－二酮衍生物
CN1188407C (zh) 具有法尼基转移酶抑制活性的咪唑衍生物及其制备方法
CN1820003A (zh) 用作肝脏x受体调节剂的吡咯－2,5－二硫酮衍生物
CN1190434C (zh) 新的杂环化合物、其制备方法和含有它们的药物组合物及其在治疗糖尿病和相关疾病中的应用
CN1044237C (zh) 4,1－苯并氧氮杂䓬衍生物和其用途
CN1276790A (zh) 酰胺基噻唑衍生物及其制备方法与药物组合物
CN1599731A (zh) 苯并硫氮杂䓬衍生物
CN1898203A (zh) 具有胆固醇吸收抑制活性的二苯基氮杂环丁酮衍生物
CN101048402A (zh) 咔唑衍生物、其溶剂合物或其药学上允许的盐
CN1617859A (zh) 5－硫烷基－4h－1,2,4－三唑衍生物及其作为药物的应用
CN1119856A (zh) Hiv逆转录酶抑制剂
CN1160397A (zh) 吡咯衍生物
CN1151148C (zh) 具有吡咯结构的法尼转移酶抑制剂及其制备方法
CN1489582A (zh) 二氢化萘衍生物及包含该衍生物作为活性成分的药物
CN1918155A (zh) 作为lxr调节剂的化合物和组合物
CN1073089C (zh) 苯并二氮杂噁衍生物、其组合物及其在药物制备中的用途
CN101080389A (zh) 具有抗增殖活性的茚满酰胺
CN1960971A (zh) 取代的吡咯烷－2－酮
CN1319938C (zh) 治疗胰岛素抵抗的邻位取代的苯甲酸衍生物
CN1177353A (zh) 具有三环式稠合杂环的新颖的奎宁环衍生物
CN1835919A (zh) (－)－2－{[2－(4－羟基苯基)乙基]－硫基}－3－[4－(2－{4－[(甲基磺酰基)氧基]苯氧基}乙基)苯基]丙酸的胺盐及其在药物中的用途
CN101103015A (zh) 作为肝脏x受体调节剂的5-硫代-1,5-二氢-2h-吡咯-2-酮衍生物
CN1090278A (zh) 血管紧张肽原酶抑制剂-n-(2-氨基-2-氧乙基)丁二酰胺衍生物
CN1058709C (zh) 治疗用酰胺类化合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication